Transmembrane mutations to FcgammaRIIA alter its association with lipid rafts: implications for receptor signaling.
Many immunoreceptors have been reported to associate with lipid rafts upon ligand binding. The way in which this association is regulated is still obscure. We investigated the roles for various domains of the human immunoreceptor FcgammaRIIA in regulating its association with lipid rafts by determining the resistance of unligated, or ligated and cross-linked, receptors to solubilization by the nonionic detergent Triton X-100, when expressed in RBL-2H3 cells. Deletion of the cytoplasmic domain, or destruction of the cytoplasmic palmitoylation site, had no effect on the association of the receptor with lipid rafts. A transmembrane mutant, A224S, lost the ability to associate with lipid rafts upon receptor cross-linking, whereas transmembrane mutants VA231-2MM and VVAL234-7GISF showed constitutive lipid raft association. Wild-type (WT) FcgammaRIIA and all transmembrane mutants activated Syk, regardless of their association with lipid rafts. WT FcgammaRIIA and mutants that associated with lipid rafts efficiently activated NF-kappaB, in an ERK-dependent manner. In contrast, WT FcgammaRIIA and the A224S mutant both presented efficient phagocytosis, while VA231-2MM and VVAL234-7GISF mutants presented lower phagocytosis, suggesting that phagocytosis may proceed independently of lipid raft association. These data identify the transmembrane domain of FcgammaRIIA as responsible for regulating its inducible association with lipid rafts and suggest that FcgammaRIIA-mediated responses, like NF-kappaB activation or phagocytosis, can be modulated by lipid raft association of the ligated receptor.
García-García
Erick
E
Immunology Department, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City D.F.-04510, Mexico.
Brown
Eric J
EJ
Rosales
Carlos
C
D000818:Animals; D002460:Cell Line; D004789:Enzyme Activation / Q000235:genetics / Q000276:immunology; D048049:Extracellular Signal-Regulated MAP Kinases / Q000276:immunology; D006801:Humans; D007152:Immunologic Capping / Q000235:genetics / Q000276:immunology; D047908:Intracellular Signaling Peptides and Proteins / Q000276:immunology; D020935:MAP Kinase Signaling System / Q000235:genetics* / Q000276:immunology; D021962:Membrane Microdomains / Q000235:genetics* / Q000276:immunology; D020125:Mutation, Missense / Q000276:immunology; D016328:NF-kappa B / Q000276:immunology; D010587:Phagocytosis / Q000235:genetics* / Q000276:immunology; D017434:Protein Structure, Tertiary / Q000235:genetics; D011505:Protein-Tyrosine Kinases / Q000276:immunology; D051381:Rats; D017452:Receptors, IgG / Q000235:genetics* / Q000276:immunology; D000072377:Syk Kinase
C445323:FCGR2A protein, human; D047908:Intracellular Signaling Peptides and Proteins; D016328:NF-kappa B; D017452:Receptors, IgG; D011505:Protein-Tyrosine Kinases; C000606896:SYK protein, human; D000072377:Syk Kinase; C000606898:Syk protein, rat; D048049:Extracellular Signal-Regulated MAP Kinases